Investigating brain disruptions linked to schizophrenia risks in adolescents

Thalamocortical disruption as a convergence point for schizophrenia risks

NIH-funded research St. Jude Children's Research Hospital · NIH-11102252

This study is looking at how certain brain changes might cause symptoms like hearing voices in teenagers with schizophrenia, using mice to help find clues that could lead to better treatments and help them stick to their medication.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11102252 on NIH RePORTER

What this research studies

This research focuses on understanding the biological mechanisms behind positive symptoms of schizophrenia, such as auditory hallucinations, particularly in adolescents aged 12 to 20. By studying mouse models with specific genetic variations known to increase schizophrenia risk, the research aims to identify disruptions in brain connections that may lead to these symptoms. The approach involves examining thalamocortical projections, which are critical for auditory processing, to uncover potential biological markers that could inform treatment strategies. The findings could help improve adherence to antipsychotic medications by providing insights into the underlying causes of these symptoms.

Who could benefit from this research

Good fit: Ideal candidates for this research are adolescents aged 12 to 20 who have genetic predispositions to schizophrenia, such as those with 22q11.2 or 3q29 microdeletion syndromes.

Not a fit: Patients who do not have the specific genetic variations associated with increased schizophrenia risk may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to better-targeted treatments for schizophrenia, reducing the severity of symptoms and improving the quality of life for affected adolescents.

How similar studies have performed: Previous research has shown promising results in understanding the genetic and biological underpinnings of schizophrenia, suggesting that this approach could yield valuable insights.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions 22q11 Chromosomal Microdeletion Syndrome22q11 Deletion Syndrome22q11.2 deletion syndrome
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.